Organization (Industry)
KARDIUM INC.
ClinicalTrials.gov lists KARDIUM INC. as lead sponsor of 10 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers KARDIUM INC.: 10 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (1)
| Disease area | Trials |
|---|---|
| Atrial Fibrillation | 9 |
Trials by start year as sponsor or collaborator (7)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2023 | 1 |
| 2021 | 3 |
| 2014 | 1 |
| 2012 | 1 |
| 2010 | 1 |
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 0 of 2 hit target (n=2) | 1 of 2 on time (n=2) |
Journals published in (3)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Journal of the American College of Cardiology | 2 |
| Circulation. Arrhythmia and electrophysiology | 1 |
| Heart rhythm | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 161 | 58 | 2025-12-16 |
Financing and grant events (1)
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2020-12-30 | Mixed securities | 116,301,952 | Form d |
FDA recalls (1)
| Product | Classification | Initiated |
|---|---|---|
| TORQ Sternal Closure Device. The common name is TWISTER, WIRE. The model number is TQ01A. The Catalog numbers are: 17-00001: TORQ Sternal Closure Device Shipping Carton (6-10 packs), Sterile and, 15-00001 (or 17-00002): TORQ Sternal Closure Device 10-pack - Sterile. The device is supplied double-pouched, inside a shelf box containing 10 devices each. Shelf boxes are shipped to customers in either a small shipping carton containing one (1) shelf box (for a total of 10 devices), or large shipping carton containing six (6) shelf boxes (for a total of 6 x 10 = 60 devices). This product is used to close the sternal wires during cardiac surgery, and it is not an implantable device. The TORQ Sternal Closure device is used during sternal closure to tension and twist standard stainless steel surgical sutures of USP size 6 or 7 (metric size 8.0 or 9.0). The TORQ device is designed for use as a standard surgical suture wire twister for sternal closure. (Surgical sutures are not provided with the device.) The TORQ device is disposable, single-use, non-implantable and supplied sterile. | Class II | 2012-08-28 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2014-05-23 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| KARDIUM Inc. | Burnaby British Columbia, CA | FDA |
Latest dated events (174)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-12 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-10-14 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-10-07 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 174 events.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, biomarker capability evidence, and biomarkers this organization publishes on.